Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)

AIMS: Elevated lipoprotein(a) [Lp(a)] is strongly associated with an increased cardiovascular disease (CVD) risk. We previously reported that pro-inflammatory activation of circulating monocytes is a potential mechanism by which Lp(a) mediates CVD. Since potent Lp(a)-lowering therapies are emerging,...

Descripción completa

Detalles Bibliográficos
Autores principales: Stiekema, Lotte C A, Prange, Koen H M, Hoogeveen, Renate M, Verweij, Simone L, Kroon, Jeffrey, Schnitzler, Johan G, Dzobo, Kim E, Cupido, Arjen J, Tsimikas, Sotirios, Stroes, Erik S G, de Winther, Menno P J, Bahjat, Mahnoush
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308540/
https://www.ncbi.nlm.nih.gov/pubmed/32268367
http://dx.doi.org/10.1093/eurheartj/ehaa171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308540/
https://www.ncbi.nlm.nih.gov/pubmed/32268367
http://dx.doi.org/10.1093/eurheartj/ehaa171

Ejemplares similares